Table 2.
Characteristics of Patients in the Two Groups and with the X2 Test for Categorical Variables
| Characteristics | Single-Site Radiotherapy | Multiple-Site Radiotherapy | P |
|---|---|---|---|
| Age(y) | 57 (50–64) | 52 (47.75–59.25) | 0.002 |
| >60 | 47 (42.3) | 21 (22.3) | |
| ≤60 | 64 (57.7) | 73 (77.7) | |
| Sex | 0.808 | ||
| Female | 75 (67.6) | 65 (69.1) | |
| Male | 36 (32.4) | 29 (30.9) | |
| Smoking Status | 0.458 | ||
| Never | 85 (76.6) | 76 (80.9) | |
| Former/current | 26 (23.4) | 18 (19.1) | |
| EGFR Mutation | 0.264 | ||
| Exon 18 | 1 (0.9) | 3 (3.2) | |
| Exon 19 | 55 (49.5) | 37 (39.4) | |
| Exon 20 | 0 (0.0) | 1 (1.1) | |
| Exon 21 | 55 (49.5) | 52 (55.3) | |
| Exon 18 and 20 | 0 (0.0) | 1 (1.1) | |
| Systemic Therapy | |||
| Platinum treatment | 80 (72.1) | 78 (83.0) | 0.064 |
| First-line EGFR TKIs therapy | 74 (66.7) | 56 (59.6) | 0.294 |
| Second-line EGFR TKIs therapy | 37 (33.3) | 38 (40.4) | 0.294 |
| Location of Metastasis | |||
| Brain | 68 (61.3) | 70 (74.5) | 0.045 |
| Bone | 84 (75.7) | 77 (81.9) | 0.278 |
| Abdomen | 2 (1.8) | 11 (11.7) | |
| Soft tissue | 1 (0.9) | 0 (0.0) | |
| The Site of Radiotherapy | |||
| Thoracic | 20 (18.0) | 81 (86.2) | <0.001 |
| Brain | 48 (43.2) | 65 (69.1) | <0.001 |
| Bone | 42 (37.8) | 54 (57.4) | 0.005 |
| Adrenal | 2 (1.8) | 6 (6.4) | |
| Liver | 0 (0.0) | 4 (4.3) | |
| Spleen | 0 (0.0) | 1 (1.0) | |
| Soft tissue | 1 (0.9) | 0 (0.0) | |
| Number of Radiotherapy | |||
| 1 | 111 (100.0) | 0 (0.0) | |
| 2 | 0 (0.0) | 71 (75.5) | |
| 3 | 0 (0.0) | 20 (21.3) | |
| 4 | 0 (0.0) | 3 (3.2) |
Note: Data are presented as n (%) or median (interquartile range).
Abbreviations: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.